Skip to main content

Table 2 Patient characteristics

From: Is shared decision-making vanishing at the end-of-life? A descriptive and qualitative study of advanced cancer patients’ involvement in specific therapies decision-making

 

n

Value

%

Age, years

29

  

 Mean

 

65,4

 

 Range

 

43–80

 

Sex

29

  

 Male

 

12

41,3

 Female

 

17

58,7

Primary tumor

   

 GI (+pancreas)

 

6

20,7

 Breast

 

5

17,2

 Respiratory + ENT

 

4

13,8

 Other solid tumor

 

5

17,2

 Leukemia

 

5

17,2

 Lymphoma

 

3

10,3

 Myeloma

 

1

3,4

Time from diagnosis, months

29

  

 Mean

 

44

 

 Range

 

0.8–186.4

 

Performance status

28

  

 Mean

 

2,4

 

 Range

 

0–4

 

 0–1

 

5

17,2

 2

 

6

20,7

 3

 

14

28,0

 4

 

3

10,3

Number of treatment lines

28

  

 Mean

 

2.8

 

 Range

 

0–6

 

 0

 

2

6,8

 1

 

3

10,3

 2

 

9

31,0

 3

 

5

17,2

 4

 

5

17,2

 >4

 

5

17,2

Quality of lifea

29

  

 Mean

 

2,9

 

 Range

 

0,2–9

 

 0–2,4

 

16

 

 2,5–4,9

 

8

 

 5–7,4

 

3

 

 7,5–10

 

2

 

Estimated Life expectancy

29

  

 <15 days

 

1

 

 15 days–3 months

 

10

 

 3–6 months

 

8

 

 6–12 months

 

5

 

 Not answered

 

5

 
  1. aestimated between 0 and 10 on a visual scale by physician